questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Globulines
Sérum-globulines
Immunoglobulines
Anticorps
Anticorps neutralisants
Anticorps neutralisants : Questions médicales fréquentes
Diagnostic
5
Anticorps
Tests de diagnostic
Anticorps neutralisants
Tests de laboratoire
Symptômes
5
Symptômes
Réponse immunitaire
Réactions indésirables
Anticorps
Maladies auto-immunes
Anticorps
Traitements
5
Thérapie
Anticorps neutralisants
Effets secondaires
Anticorps
Complications
5
Maladies auto-immunes
Anticorps
Interactions médicamenteuses
Anticorps
Surveillance
Complications
Facteurs de risque
5
Immunodépression
Facteurs de risque
Antécédents médicaux
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Anticorps neutralisants : Questions médicales les plus fréquentes",
"headline": "Anticorps neutralisants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Anticorps neutralisants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-02",
"dateModified": "2026-03-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Anticorps neutralisants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Anticorps",
"url": "https://questionsmedicales.fr/mesh/D000906",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps",
"code": {
"@type": "MedicalCode",
"code": "D000906",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps neutralisants à large spectre",
"alternateName": "Broadly Neutralizing Antibodies",
"url": "https://questionsmedicales.fr/mesh/D000080908",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps neutralisants à large spectre",
"code": {
"@type": "MedicalCode",
"code": "D000080908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.244.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Anticorps neutralisants",
"alternateName": "Antibodies, Neutralizing",
"code": {
"@type": "MedicalCode",
"code": "D057134",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ian A Wilson",
"url": "https://questionsmedicales.fr/author/Ian%20A%20Wilson",
"affiliation": {
"@type": "Organization",
"name": "Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA."
}
},
{
"@type": "Person",
"name": "Andrew B Ward",
"url": "https://questionsmedicales.fr/author/Andrew%20B%20Ward",
"affiliation": {
"@type": "Organization",
"name": "Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA."
}
},
{
"@type": "Person",
"name": "Jun Zhang",
"url": "https://questionsmedicales.fr/author/Jun%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, PR China."
}
},
{
"@type": "Person",
"name": "David Montefiori",
"url": "https://questionsmedicales.fr/author/David%20Montefiori",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA."
}
},
{
"@type": "Person",
"name": "Davide Corti",
"url": "https://questionsmedicales.fr/author/Davide%20Corti",
"affiliation": {
"@type": "Organization",
"name": "Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: dcorti@vir.bio."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37235376",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/toxins15050342"
}
},
{
"@type": "ScholarlyArticle",
"name": "An Antibody-Dependent Cellular Cytotoxicity Assay for Detecting Ocrelizumab Neutralizing Antibody.",
"datePublished": "2023-10-02",
"url": "https://questionsmedicales.fr/article/37783946",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1208/s12248-023-00858-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neutralizing Antibody Sample Testing and Report Harmonization.",
"datePublished": "2024-07-12",
"url": "https://questionsmedicales.fr/article/38992280",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1208/s12248-024-00955-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neutralizing Antibody Validation Testing and Reporting Harmonization.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37421491",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1208/s12248-023-00830-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Broadly neutralizing antibodies against COVID-19.",
"datePublished": "2023-06-06",
"url": "https://questionsmedicales.fr/article/37285620",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.coviro.2023.101332"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Globulines",
"item": "https://questionsmedicales.fr/mesh/D005916"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sérum-globulines",
"item": "https://questionsmedicales.fr/mesh/D012712"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007136"
},
{
"@type": "ListItem",
"position": 7,
"name": "Anticorps",
"item": "https://questionsmedicales.fr/mesh/D000906"
},
{
"@type": "ListItem",
"position": 8,
"name": "Anticorps neutralisants",
"item": "https://questionsmedicales.fr/mesh/D057134"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Anticorps neutralisants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Anticorps neutralisants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Anticorps neutralisants",
"description": "Comment détecte-t-on les anticorps neutralisants ?\nQuels tests sont utilisés pour les anticorps neutralisants ?\nPeut-on mesurer leur efficacité ?\nLes anticorps neutralisants sont-ils spécifiques ?\nQuel rôle jouent-ils dans le diagnostic des infections ?",
"url": "https://questionsmedicales.fr/mesh/D057134#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Anticorps neutralisants",
"description": "Les anticorps neutralisants causent-ils des symptômes ?\nComment les anticorps neutralisants affectent-ils les symptômes ?\nPeuvent-ils provoquer des réactions indésirables ?\nLes symptômes varient-ils selon le pathogène ?\nLes anticorps neutralisants sont-ils liés à des maladies auto-immunes ?",
"url": "https://questionsmedicales.fr/mesh/D057134#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Anticorps neutralisants",
"description": "Les anticorps neutralisants peuvent-ils prévenir les infections ?\nComment renforcer la production d'anticorps neutralisants ?\nLes anticorps neutralisants sont-ils disponibles en prophylaxie ?\nLes mesures d'hygiène aident-elles à la prévention ?\nLes anticorps neutralisants sont-ils efficaces contre les variants ?",
"url": "https://questionsmedicales.fr/mesh/D057134#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Anticorps neutralisants",
"description": "Les anticorps neutralisants sont-ils utilisés en thérapie ?\nComment sont administrés les anticorps neutralisants ?\nQuels sont les effets secondaires des traitements ?\nLes anticorps neutralisants sont-ils efficaces contre tous les virus ?\nPeut-on développer une résistance aux anticorps neutralisants ?",
"url": "https://questionsmedicales.fr/mesh/D057134#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Anticorps neutralisants",
"description": "Quelles complications peuvent survenir avec les anticorps neutralisants ?\nLes anticorps neutralisants peuvent-ils aggraver des maladies ?\nY a-t-il des risques de thrombose ?\nLes anticorps neutralisants peuvent-ils interférer avec d'autres traitements ?\nLes complications sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D057134#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Anticorps neutralisants",
"description": "Quels facteurs augmentent le besoin d'anticorps neutralisants ?\nL'âge influence-t-il la réponse aux anticorps ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe mode de vie affecte-t-il la production d'anticorps ?\nLes comorbidités influencent-elles l'efficacité des anticorps ?",
"url": "https://questionsmedicales.fr/mesh/D057134#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on les anticorps neutralisants ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont détectés par des tests sérologiques spécifiques, comme les tests ELISA."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les anticorps neutralisants ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de neutralisation virale et les tests d'inhibition sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer leur efficacité ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'efficacité est mesurée par des titres d'anticorps dans le sérum."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants sont-ils spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent spécifiques à un pathogène particulier, comme un virus."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent-ils dans le diagnostic des infections ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils aident à confirmer une infection antérieure ou en cours par un pathogène."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants causent-ils des symptômes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils ne causent pas de symptômes, mais leur absence peut indiquer une vulnérabilité."
}
},
{
"@type": "Question",
"name": "Comment les anticorps neutralisants affectent-ils les symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire la gravité des symptômes en neutralisant les agents pathogènes."
}
},
{
"@type": "Question",
"name": "Peuvent-ils provoquer des réactions indésirables ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des réactions allergiques peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le pathogène ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type d'infection et de l'agent pathogène."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants sont-ils liés à des maladies auto-immunes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être impliqués dans certaines maladies auto-immunes, mais ce n'est pas courant."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants peuvent-ils prévenir les infections ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire le risque d'infection lorsqu'ils sont administrés préventivement."
}
},
{
"@type": "Question",
"name": "Comment renforcer la production d'anticorps neutralisants ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination est un moyen efficace de stimuler la production d'anticorps neutralisants."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants sont-ils disponibles en prophylaxie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains anticorps neutralisants sont utilisés en prophylaxie pour des groupes à risque."
}
},
{
"@type": "Question",
"name": "Les mesures d'hygiène aident-elles à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mesures d'hygiène comme le lavage des mains réduisent le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants sont-ils efficaces contre les variants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend des mutations; certains variants peuvent échapper à la neutralisation."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants sont-ils utilisés en thérapie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont utilisés dans des traitements pour des infections virales comme COVID-19."
}
},
{
"@type": "Question",
"name": "Comment sont administrés les anticorps neutralisants ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement administrés par injection intraveineuse ou sous-cutanée."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions au site d'injection et des allergies."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants sont-ils efficaces contre tous les virus ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur efficacité varie selon le virus et le type d'anticorps."
}
},
{
"@type": "Question",
"name": "Peut-on développer une résistance aux anticorps neutralisants ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains virus peuvent muter et échapper à la neutralisation par ces anticorps."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les anticorps neutralisants ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques et des effets indésirables au site d'injection peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants peuvent-ils aggraver des maladies ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas, ils peuvent exacerber des maladies auto-immunes existantes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de thrombose ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cas de thrombose ont été rapportés, mais ils sont rares et nécessitent une surveillance."
}
},
{
"@type": "Question",
"name": "Les anticorps neutralisants peuvent-ils interférer avec d'autres traitements ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent interagir avec certains médicaments, nécessitant une évaluation médicale."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont généralement rares, mais une surveillance est recommandée."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin d'anticorps neutralisants ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes immunodéprimées ou à risque élevé d'infection en ont souvent besoin."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la réponse aux anticorps ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir une réponse immunitaire moins efficace."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies respiratoires ou auto-immunes peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il la production d'anticorps ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain, incluant une bonne nutrition, peut améliorer la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Les comorbidités influencent-elles l'efficacité des anticorps ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les comorbidités peuvent réduire l'efficacité des anticorps neutralisants."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 24/03/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
The Skaggs Institute for Chemical Biology, the Scripps Research Institute, La Jolla, CA 92037, USA.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, PR China.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: dcorti@vir.bio.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 50931 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. Electronic address: florian.klein@uk-koeln.de.
Publications dans "Anticorps neutralisants" :
3 publications dans cette catégorie
Affiliations :
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Affiliations :
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Affiliations :
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Affiliations :
HIV Vaccine Trials Network, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA; email: mkaruna@fredhutch.org, lcorey@fredhutch.org.
Departments of Medicine and Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA.
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Affiliations :
Ragon Institute of MGH, MIT and Harvard, Cambridge.
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Affiliations :
Ragon Institute of MGH, MIT and Harvard, Cambridge.
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Affiliations :
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA.
Publications dans "Anticorps neutralisants" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.
Publications dans "Anticorps neutralisants" :
Though the formation of neutralizing antibodies (NAbs) during treatment with botulinum neurotoxin is rare, their presence may nonetheless affect the biological activity of botulinum toxin and negative...
Ocrelizumab (OCREVUS®) is a humanized anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPM...
Immunogenicity testing and characterization is an important part of understanding the immune response to administration of a protein therapeutic. Neutralizing antibody (NAb) assays are used to charact...
Evolving immunogenicity assay performance expectations and a lack of harmonized neutralizing antibody validation testing and reporting tools have resulted in significant time spent by health authoriti...
The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an effective treatment. Since SARS-C...
The discovery of broadly neutralizing HIV-1 antibodies (bNAbs) has provided a framework for vaccine design and created new hope toward an HIV-1 cure. These antibodies recognize the HIV-1 Envelope and ...
Parallel evaluation of bNAbs nonneutralizing activities using in vivo and in vitro models have revealed how their importance varies across antibodies and strains. Nonneutralizing bNAbs functions targe...
Nonneutralizing activities of bNAbs target infected cells, virions, and immune complexes, promoting viral clearance and possibly improving immune responses. We review how these functions participate t...
Combination monoclonal broadly neutralizing antibodies (bnAbs) are currently being developed for preventing HIV-1 acquisition. Recent work has focused on predicting in vitro neutralization potency of ...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has challenged the effectiveness of current therapeutic regimens. Here, we aimed to develop a potent SARS-CoV-2 a...
SKAI-DS84 was identified through phage display, and we performed pseudovirus neutralization assays, authentic virus neutralization assays, and in vivo neutralization efficacy evaluations. Furthermore,...
The selected clones were converted to human IgG, and among them, SKAI-DS84 was selected for further analyses based on its binding affinity with the variant RBDs. Using pseudoviruses, we confirmed that...
We identified, produced, and tested the neutralizing effect of SKAI-DS84 antibody. Our results highlight that SKAI-DS84 could be a potential neutralizing antibody against SARS-CoV-2 and its variants....
HIV has been reported to interfere with protective vaccination against multiple pathogens, usually through the decreased effectiveness of the antibody responses. We aimed to assess neutralizing antibo...
The study was conducted at the Ambulatory Treatment Center of the National HIV Program, in charge of over 6000 PLWH, and the health center of FCRM in Brazzaville, Republic of the Congo. Participants w...
We collected oropharyngeal and blood samples from 1016 participants including 684 PLWH and 332 PLWOH. Both PLWH and PLWOH elicited high levels of antibody responses after complete vaccination with ina...
The results from this study underline the importance of implementing integrated health systems that provide PLWH the opportunity to benefit HIV prevention and care, at the same time while monitoring t...
Drug-resistant Pseudomonas aeruginosa (PA) poses an emerging threat to human health with urgent need for alternative therapeutic approaches. Here, we deciphered the B cell and antibody response to the...